Monopar advances first novel Wilson disease therapy in decades toward FDA approval

Monopar has initiated a rolling NDA submission to the FDA for ALXN1840, a first-in-class copper-sequestering agent for Wilson disease that operates via a novel mechanism distinct from existing chelators and shows improved neurological outcomes in Phase III trial data. Approval would mark the first new mechanism of action for this rare genetic disorder in decades.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.